Skip to content

Avalo Therapeutics AVTX Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

Absci Corporation logo
Absci CorporationABSI
$8.95M+54.3%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$117.2M-34.5%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$160.99M+3,322%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$954.59M+1,800%
Enterprise value$929.6M-1,353%
P/S1,909.2×+1,868×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%
Debt / equity0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avalo Therapeutics's common stock shares outstanding?
Avalo Therapeutics (AVTX) reported common stock shares outstanding of $23.8M in Q1 2026.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.